WO2024259428A3 - Composés oestrogènes et formulations pour complications associées à la grossesse - Google Patents

Composés oestrogènes et formulations pour complications associées à la grossesse Download PDF

Info

Publication number
WO2024259428A3
WO2024259428A3 PCT/US2024/034368 US2024034368W WO2024259428A3 WO 2024259428 A3 WO2024259428 A3 WO 2024259428A3 US 2024034368 W US2024034368 W US 2024034368W WO 2024259428 A3 WO2024259428 A3 WO 2024259428A3
Authority
WO
WIPO (PCT)
Prior art keywords
formulations
gestation
related complications
estrogenic compounds
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2024/034368
Other languages
English (en)
Other versions
WO2024259428A2 (fr
Inventor
Fatima CHLEILAT
Michael P. Snyder
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Leland Stanford Junior University
Original Assignee
Leland Stanford Junior University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Leland Stanford Junior University filed Critical Leland Stanford Junior University
Publication of WO2024259428A2 publication Critical patent/WO2024259428A2/fr
Publication of WO2024259428A3 publication Critical patent/WO2024259428A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/566—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol having an oxo group in position 17, e.g. estrone

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

L'invention concerne des formulations, des composés et des procédés pour prolonger la grossesse et pour le traitement de complications associées à la grossesse. Les traitements comprennent l'administration d'un composé oestrogène pour atténuer les contractions utérines.
PCT/US2024/034368 2023-06-16 2024-06-17 Composés oestrogènes et formulations pour complications associées à la grossesse Ceased WO2024259428A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202363508763P 2023-06-16 2023-06-16
US63/508,763 2023-06-16

Publications (2)

Publication Number Publication Date
WO2024259428A2 WO2024259428A2 (fr) 2024-12-19
WO2024259428A3 true WO2024259428A3 (fr) 2025-03-13

Family

ID=93852720

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2024/034368 Ceased WO2024259428A2 (fr) 2023-06-16 2024-06-17 Composés oestrogènes et formulations pour complications associées à la grossesse

Country Status (1)

Country Link
WO (1) WO2024259428A2 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN119505212B (zh) * 2025-01-17 2025-04-11 合肥工业大学 Pbat/竹粉相容和交联一体化助剂、制备方法及应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110118224A1 (en) * 2008-07-28 2011-05-19 Preglem Sa Use of steroid sulfatase inhibitors for the treatment of preterm labor
US20220339176A1 (en) * 2019-09-23 2022-10-27 The Board Of Trustees Of The Leland Stanford Junior University Methods of Treatments to Prolong Gestation and Complications of Menstruation or Gestation

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110118224A1 (en) * 2008-07-28 2011-05-19 Preglem Sa Use of steroid sulfatase inhibitors for the treatment of preterm labor
US20220339176A1 (en) * 2019-09-23 2022-10-27 The Board Of Trustees Of The Leland Stanford Junior University Methods of Treatments to Prolong Gestation and Complications of Menstruation or Gestation

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
AKINWUNMI BABATUNDE, MING WAI-KIT: "Evaluating Vaginal Progesterone in Preventing Recurrent Preterm Birth: A Call to Action", JAMA NETWORK OPEN, JAMA NETWORK, vol. 5, no. 10, 3 October 2022 (2022-10-03), pages e2242247, XP093291468, ISSN: 2574-3805, DOI: 10.1001/jamanetworkopen.2022.42247 *
DATABASE PUBCHEM COMPOUND 25 March 2005 (2005-03-25), XP093291462, Database accession no. 3269 *
GARFIELD R E, SHI S-Q, SHI L.: "Use of progesterone and progestin analogs for inhibition of preterm birth and other uterine contractility disorders", FACTS, VIEWS AND VISION IN OBGYN, vol. 4, no. 4, 1 January 2012 (2012-01-01), pages 237 - 244, XP093291456 *
TAYLOR JESSICA, SHARP ANDREW, RANNARD STEVE P., ARROWSMITH SARAH, MCDONALD TOM O.: "Nanomedicine strategies to improve therapeutic agents for the prevention and treatment of preterm birth and future directions", NANOSCALE ADVANCES, ROYAL SOCIETY OF CHEMISTRY, vol. 5, no. 7, 28 March 2023 (2023-03-28), pages 1870 - 1889, XP093291460, ISSN: 2516-0230, DOI: 10.1039/D2NA00834C *

Also Published As

Publication number Publication date
WO2024259428A2 (fr) 2024-12-19

Similar Documents

Publication Publication Date Title
CA2281755C (fr) Composition pharmaceutique a usage local contenant un agent cholinergique ou un inhibiteur calcique
JP2023503309A5 (fr)
US6159944A (en) Method for treating painful conditions of the anal region and compositions therefor
JP2023503303A5 (fr)
EP1063990B1 (fr) Extrait enrichi en biochanine pour le traitement de troubles lies aux oestrogenes
WO2024259428A3 (fr) Composés oestrogènes et formulations pour complications associées à la grossesse
JP2003503313A5 (fr)
KR20110045065A (ko) 월경 억제, 피임 및 호르몬 대체 요법을 위한 약제 및 이를 투여하는 방법
Smith Drug treatment of varicose veins, venous edema, and ulcers
CZ282840B6 (cs) Farmaceutické prostředky
MX2023005078A (es) Nuevas formas cristalinas de un compuesto inhibidor de kras g12c.
HUP0100012A2 (hu) Makrolid vegyületek alkalmazása rák és a makuláns elváltozások kezelésére
MX2025001642A (es) Tratamiento del cancer de piel
WO2019142124A4 (fr) Compositions pharmaceutiques pour le traitement du vitiligo
NZ521315A (en) Exemestane for first-line treatment of breast cancer
CA3013734C (fr) Methode et composition destinees au traitement et a la prevention d'une vaste gamme d'affections virales
US20180271786A1 (en) Enema for rectal application
CN105147703A (zh) 黄柏酮在制备防治溃疡性结肠炎的药物或食品中的应用
WO2023183816A3 (fr) Compositions et méthodes pour favoriser la cicatrisation des plaies et réduire au minimum la formation d'une cicatrice
EP1641470B1 (fr) Compositions vaginales pour le traitement des infections et des traumas du tissu pelvien
CN104983728A (zh) 金合欢素在制备防治溃疡性结肠炎的药物或食品中的应用
PH12022553502A1 (en) Topical formulations of (1s)-1-phenyl-2-pyridin-2-ylethanamine
Hellman Neomycin, a new antibiotic active against streptomycin-resistant bacteria, including tuberculosis organisms: Waksman, Selman A., and Lechevalier, Hubert A.: Science 109: 305, March 25, 1949
JP2023502251A (ja) ファルネソイドｘ受容体（ｆｘｒ）を介した転写応答を誘導または促進する方法
CN105078960A (zh) 芫花素在制备防治溃疡性结肠炎的药物或食品中的应用

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 24824354

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE